<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-09-15" updated="2019-12-02">
  <drugbank-id primary="true">DB07565</drugbank-id>
  <name>Chloramphenicol succinate</name>
  <description/>
  <cas-number>3544-94-3</cas-number>
  <unii>ZCX619U9A1</unii>
  <average-mass>423.202</average-mass>
  <monoisotopic-mass>422.028370912</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as nitrobenzenes. These are compounds containing a nitrobenzene moiety, which consists of a benzene ring with a carbon bearing a nitro group.</description>
    <direct-parent>Nitrobenzenes</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Nitrobenzenes</subclass>
    <alternative-parent>Alkyl chlorides</alternative-parent>
    <alternative-parent>Aromatic alcohols</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Fatty acid esters</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Nitroaromatic compounds</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic oxoazanium compounds</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Alkyl chloride</substituent>
    <substituent>Alkyl halide</substituent>
    <substituent>Allyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Aromatic alcohol</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>C-nitro compound</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Fatty acid ester</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Nitroaromatic compound</substituent>
    <substituent>Nitrobenzene</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitro compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxoazanium</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001357</drugbank-id>
      <name>Chloramphenicol sodium succinate</name>
      <unii>872109HX6B</unii>
      <cas-number>982-57-0</cas-number>
      <inchikey>RPLOPBHEZLFENN-HTMVYDOJSA-M</inchikey>
      <average-mass>445.18</average-mass>
      <monoisotopic-mass>444.0103151</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Chloramphenicol hemisuccinate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Chloramphenicol Sodium Succinate</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>1 g/10mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062365</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chloramphenicol Sodium Succinate</name>
      <labeller>General Injectables &amp; Vaccines</labeller>
      <ndc-id/>
      <ndc-product-code>52584-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-01</started-marketing-on>
      <ended-marketing-on>2017-01-18</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>1 g/10mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062365</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chloromycetin Sodium Succinate</name>
      <labeller>Monarch Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>61570-405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-02-20</started-marketing-on>
      <ended-marketing-on>2007-10-05</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050155</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Chloromycetin Sodium Succinate</name>
      <ingredients>Chloramphenicol succinate</ingredients>
    </mixture>
    <mixture>
      <name>Chloramphenicol Sodium Succinate</name>
      <ingredients>Chloramphenicol succinate</ingredients>
    </mixture>
    <mixture>
      <name>Chloramphenicol Sodium Succinate</name>
      <ingredients>Chloramphenicol succinate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Nitro Compounds</category>
      <mesh-id>D009574</mesh-id>
    </category>
    <category>
      <category>Nitrobenzenes</category>
      <mesh-id>D009578</mesh-id>
    </category>
    <category>
      <category>Propylene Glycols</category>
      <mesh-id>D011409</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>1 g/10mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>100 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>2jkn</pdb-entry>
    <pdb-entry>2w5p</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Chloramphenicol succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Chloramphenicol succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with (S)-Warfarin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.34</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.12e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-[(2R,3R)-2-(2,2-dichloroacetamido)-3-hydroxy-3-(4-nitrophenyl)propoxy]-4-oxobutanoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>chloramphenicol succinate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>423.202</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>422.028370912</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C15H16Cl2N2O8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C15H16Cl2N2O8/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21)/t10-,13-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LIRCDOVJWUGTMW-ZWNOBZJWSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>156.07</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>92.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>37.74</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.65</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>656580</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>99444036</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C11727</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>570947</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>CL8</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Chloramphenicol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201281</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0001544</id>
      <name>Dr hemagglutinin structural subunit</name>
      <organism>Escherichia coli</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P24093" source="Swiss-Prot">
        <name>Dr hemagglutinin structural subunit</name>
        <general-function/>
        <specific-function>Hemagglutinins of uropathogenic E.coli mediate adherence to the upper urinary tract. These adhesins bind to the Dr blood group antigen and also agglutinate human erythrocytes in the presence of D-mannose (mannose-resistant hemagglutination (MRHA)).</specific-function>
        <gene-name>draA</gene-name>
        <locus/>
        <cellular-location>Fimbrium</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-21</signal-regions>
        <theoretical-pi>7.25</theoretical-pi>
        <molecular-weight>17058.095</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="562">Escherichia coli</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M62834</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>145801</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P24093</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRAA_ECOLX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Dr hemagglutinin structural subunit precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011094|Dr hemagglutinin structural subunit
MKKLAIMAAASMVFAVSSAHAGFTPSGTTGTTKLTVTEECQVRVGDLTVAKTRGQLTDAA
PIGPVTVQALGCDARQVALKADTDNFEQGKFFLISDNNRDKLYVNIRPTDNSAWTTDNGV
FYKNDVGSWGGIIGIYVDGQQTNTPPGNYTLTLTGGYWAK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0003065|483 bp
ATGAAAAAATTAGCGATCATGGCCGCGGCCAGCATGGTGTTCGCCGTGAGCTCCGCGCAT
GCTGGGTTCACCCCGAGTGGCACCACCGGCACCACCAAACTCACAGTTACCGAAGAGTGC
CAGGTACGGGTTGGTGACCTGACCGTGGCTAAGACTCGTGGCCAACTGACGGACGCAGCA
CCAATAGGGCCGGTCACCGTGCAAGCGCTGGGATGCGACGCCCGCCAGGTCGCGTTGAAG
GCAGACACCGATAACTTCGAACAGGGCAAGTTCTTCCTGATCAGCGACAACAATAGGGAT
AAGCTCTATGTCAATATACGGCCTACGGATAACTCCGCCTGGACGACCGACAATGGTGTC
TTCTACAAAAACGATGTCGGGAGCTGGGGTGGAATTATCGGGATCTACGTAGATGGGCAA
CAAACGAACACACCGCCCGGCAACTACACACTGACCCTGACCGGGGGTTACTGGGCAAAA
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF04619</identifier>
            <name>Adhesin_Dr</name>
          </pfam>
          <pfam>
            <identifier>PF12393</identifier>
            <name>Dr_adhesin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>pilus</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>